Rezolute, Inc. received and approved a request to provide its antibody therapy, RZ358, to a patient with intractable hypoglycemia caused by an insulinoma, marking the first time the therapy is used for this indication.
AI Assistant
REZOLUTE INC
2023
8 K
Find Answers
Ask about any part of the document to get insights, explanations, or key details.